Literature DB >> 8907383

Susceptibility of corneal and conjunctival pathogens to ciprofloxacin.

H P Knauf1, R Silvany, P M Southern, R C Risser, S E Wilson.   

Abstract

Ciprofloxacin 0.3% ophthalmic solution has been shown to be effective in the treatment of bacterial keratitis and conjunctivitis, and many physicians use ciprofloxacin as sole therapy in these conditions. In this retrospective study, we found seven of 84 isolates from corneal and conjunctival cultures that were resistant to ciprofloxacin. All of the resistant organisms were gram positive. Six of the isolates (Staphylococcus aureus, Staphylococcus hominis, and four isolates of the Streptococcus viridans group) were from corneal cultures, and one (Staphylococcus aureus) was from a conjunctival culture. Yearly records of systemic isolates from 1988 to 1993 (n = 35,308) demonstrated a statistically significant decrease in susceptibility for several organisms that are common pathogens in the conjunctiva and cornea: Pseudomonas aeruginosa (95-90%, p = 0.001); Staphylococcus aureus (96-87%, p < 0.0001); Staphylococcus spp., coagulase negative (97-81%, p < 0.0001); Enterococcus spp. (92-79%, p < 0.0001); Acinetobacter anitratus (97-77%, p = 0.0006); and Enterobacter cloacae (100-96%, p = 0.03). Although the susceptibility of corneal and conjunctival isolates in this series remained relatively high (91.7%), a much larger series of systemic isolates that are common ocular pathogens revealed a statistically significant increase in resistance to ciprofloxacin over the preceding 5 years.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8907383

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  9 in total

1.  In vitro antibiotic resistance in bacterial keratitis in London.

Authors:  S J Tuft; M Matheson
Journal:  Br J Ophthalmol       Date:  2000-07       Impact factor: 4.638

2.  The use of eardrops in an ENT department.

Authors:  S Natsch; E A Mylanus; J J Mulder; Y A Hekster
Journal:  Pharm World Sci       Date:  1999-12

3.  Novel antibiotic regime for pseudomonal scleritis complicating scleral buckling surgery.

Authors:  Deric De Wit; Douglas Newman
Journal:  BMJ Case Rep       Date:  2010-04-29

4.  Fluoroquinolone and fortified antibiotics for treating bacterial corneal ulcers.

Authors:  N Gangopadhyay; M Daniell; L Weih; H R Taylor
Journal:  Br J Ophthalmol       Date:  2000-04       Impact factor: 4.638

5.  Esculentin-1a(1-21)NH2: a frog skin-derived peptide for microbial keratitis.

Authors:  Satya Sree N Kolar; Vincenzo Luca; Hasna Baidouri; Giuseppe Mannino; Alison M McDermott; Maria Luisa Mangoni
Journal:  Cell Mol Life Sci       Date:  2014-08-03       Impact factor: 9.261

6.  The use of antimicrobial peptides in ophthalmology: an experimental study in corneal preservation and the management of bacterial keratitis.

Authors:  Mark J Mannis
Journal:  Trans Am Ophthalmol Soc       Date:  2002

7.  Bacterial Keratitis: Isolated Organisms and Antibiotic Resistance Patterns in San Francisco.

Authors:  Michelle Y Peng; Vicky Cevallos; Stephen D McLeod; Thomas M Lietman; Jennifer Rose-Nussbaumer
Journal:  Cornea       Date:  2018-01       Impact factor: 2.651

8.  Medical management approach to infectious keratitis.

Authors:  Nikhil S Gokhale
Journal:  Indian J Ophthalmol       Date:  2008 May-Jun       Impact factor: 1.848

9.  Clinical Features and Molecular Characteristics of Methicillin-Susceptible Staphylococcus aureus Ocular Infection in Taiwan.

Authors:  Yueh-Ling Chen; Eugene Yu-Chuan Kang; Lung-Kun Yeh; David H K Ma; Hsin-Yuan Tan; Hung-Chi Chen; Kuo-Hsuan Hung; Yhu-Chering Huang; Ching-Hsi Hsiao
Journal:  Antibiotics (Basel)       Date:  2021-11-25
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.